El-Baraky, Iman A.; Abbassi, Maggie M.; Ebeid, Fatma S.; Hassany, Mohamed; Sabry, Nirmeen A.; El-Sayed, Manal H. published the artcile< Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients>, Formula: C9H13N2O9P, the main research area is beta thalassemia major sofosbuvir ledipasvir Hepatitis C virus; Hepatitis C virus; Ledipasvir; Pharmacokinetics; Sofosbuvir; Thalassemia.
Hepatitis C virus (HCV) infected adolescents with beta-thalassemia major (BTM) are considered a potential population for HCV micro-elimination model development where BTM may neg. impact the pharmacokinetic exposure parameters of sofosbuvir/ledipasvir (SOF/LED).The study aimed at studying the effect of BTM on SOF/LED and SOF metabolite (GS-331007) pharmacokinetics.A prospective, controlled study recruiting BTM and control HCV infected adolescents (Clinicaltrials.gov identifier-NCT04353986). Pharmacokinetic exposure to GS-331007 and LED was the primary pharmacokinetic outcome. No-effect boundaries were set to 90confidence interval (CI) of exposure geometric mean ratio (GMR) within 70-143. Dose suitability was based on the 90CI of exposure GMR within 50-200compared to adults. The percentage of patients achieving sustained virol. response 12 wk post-treatment (SVR12) was the primary efficacy endpoint.Thirteen patients were enrolled per study group. All patients were included in the pharmacokinetic anal. (n=26). BTM patients showed lower GS-331007 and LED exposure that could, resp., be as low as 45.4and 36.1compared to their control group. GS-331007 exposure in BTM patients was nearly half (56.8, 90CI 45.3-71.2) that observed in adults. Despite that low drug exposure in 46.2of BTM patients may alert dose unsuitability, they achieved SVR12. Moreover, patients with total bilirubin ≥1.93 mg/dL were predicted to have low GS-331007 exposure (0.913 receiver operating characteristic area under the curve with sensitivity and specificity >80).The identified systematically lower drug exposure in BTM patients might partially explain relapses or treatment failures among BTM patients reported in other studies. BTM may be a hurdle towards implementing HCV micro-elimination model that may necessitate dose-adjustment.
Clinics and Research in Hepatology and Gastroenterology published new progress about Geometric phase. 58-97-9 belongs to class tetrahydrofurans, and the molecular formula is C9H13N2O9P, Formula: C9H13N2O9P.
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem